Rodney Elwood Infante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rodney Elwood Infante has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Puneeth Iyengar
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
15 shared publications - Arun Radhakrishnan
Department of Molecular Genetics, University of Texas Southwestern Medical Center
7 shared publications Bhavani S. Gannavarapu
Department of Radiation Oncology
7 shared publicationsArun Gupta
6 shared publicationsChul Ahn
School of Public Health University of Texas Southwestern Medical Center Dallas Texas USA
6 shared publicationsLina Abi-Mosleh
Department of Molecular Genetics University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390
5 shared publications
Latest Publications
- 19 November 2026
- Published byĀ ElsevierĀ inĀ Cell Chemical Biology
- Vol.Ā 33 Ā (11) , 1568-1570
Targeting pseudokinases: A STRADegy for tumor-suppressor activation
- 19 November 2026
- Published byĀ ElsevierĀ inĀ Cell Chemical Biology
- Vol.Ā 33 Ā (11) , 1568-1570
Targeting pseudokinases: A STRADegy for tumor-suppressor activation
- Top Cited PapersOpen Access
- 30 January 2026
- Published byĀ Springer NatureĀ inĀ Nature Communications
- Vol.Ā 17 Ā (1)
Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15
Cachexia is a wasting syndrome involving adipose, muscle, and body weight loss in cancer patients. Tumor loss-of-function mutations in STK11 / LKB1 , a regulator of AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are linked to weight loss in non-small cell lung cancer (NSCLC) patients. This study examines the role of the integrated stress response (ISR) cytokine growth differentiation factor 15 (GDF15) in regulating cachexia using patient-derived and engineered STK11/LKB1 -mutant NSCLC lines. Tumor cell-derived serum GDF15 levels are elevated in mice bearing these tumors. Treatment with a GDF15-neutralizing antibody or silencing GDF15 from tumor cells prevents adipose/muscle loss, strength decline, and weight reduction, identifying tumors cells as the GDF15 source. Restoring wild-type STK11/LKB1 in NSCLC lines with endogenous STK11/LKB1 loss reverses the ISR and reduces GDF15 expression rescuing the cachexia phenotype. Collectively, these findings implicate tumor-derived GDF15 as a key mediator and therapeutic target in STK11/LKB1 -mutant NSCLC-associated cachexia.
- 30 January 2026
- Published byĀ Springer NatureĀ inĀ Nature Communications
- Vol.Ā 17 Ā (1)
Top Cited PapersOpen AccessCancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15
Cachexia is a wasting syndrome involving adipose, muscle, and body weight loss in cancer patients. Tumor loss-of-function mutations in STK11 / LKB1 , a regulator of AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are linked to weight loss in non-small cell lung cancer (NSCLC) patients. This study examines the role of the integrated stress response (ISR) cytokine growth differentiation factor 15 (GDF15) in regulating cachexia using patient-derived and engineered STK11/LKB1 -mutant NSCLC lines. Tumor cell-derived serum GDF15 levels are elevated in mice bearing these tumors. Treatment with a GDF15-neutralizing antibody or silencing GDF15 from tumor cells prevents adipose/muscle loss, strength decline, and weight reduction, identifying tumors cells as the GDF15 source. Restoring wild-type STK11/LKB1 in NSCLC lines with endogenous STK11/LKB1 loss reverses the ISR and reduces GDF15 expression rescuing the cachexia phenotype. Collectively, these findings implicate tumor-derived GDF15 as a key mediator and therapeutic target in STK11/LKB1 -mutant NSCLC-associated cachexia.
- Open Access
- 1 January 2026
- Published byĀ Biophysical Society of ChinaĀ inĀ Biophysics Reports
- Vol.Ā 12
Targeting the GDF15-GFRAL pathway in NSCLC cachexia: from stress responses to targeted therapies
- 1 January 2026
- Published byĀ Biophysical Society of ChinaĀ inĀ Biophysics Reports
- Vol.Ā 12
Open AccessTargeting the GDF15-GFRAL pathway in NSCLC cachexia: from stress responses to targeted therapies
- Open Access
- 1 January 2026
- Published byĀ WileyĀ inĀ Journal of Cachexia, Sarcopenia and Muscle
- Vol.Ā 17 Ā (2) , e70266
Undetected Weight Loss Associates With Upstaging in Cancer Patients
Background: Unintentional weight loss (UWL) is the primary diagnostic parameter for cancer cachexia in the clinic. Prompt identification of UWL can lead to earlier diagnoses and interventions for cancer. This study investigates the frequency and timing of UWL documentation and diagnoses in a cohort of cancer patients with measured UWL and sought to understand how recognition of UWL is related to stage of disease at cancer diagnosis. Methods: A retrospective cohort of adult gastrointestinal and nonāsmall cell lung cancer patients with measured UWL was evaluated. Body weight histories were manually reviewed for UWL. Patients with intentional weight loss, weight loss related to fluid status or weight loss with unclear intention were excluded. Records were assessed for the use of UWLārelated International Classification of Diseases codes and documentation of UWL. ULW was considered missed if it was not documented or diagnosed by a healthcare provider. Associations between weight loss over time, documentation and/or diagnosis of UWL and stage of disease at cancer diagnosis were investigated through repeated measures mixed models and univariate and multivariate tests. Results: In total, 374 patients (24%) met the definition of UWL with an average weight loss of 8.6% ± 0.3%. UWL was missed in 161 (43%) patients with cancer cachexia. The odds of undetected UWL were greater in patients < 65 years old, with NSCLC, with obesity and who were White. In the 213 patients with recognized UWL, the documentation of UWL occurred approximately 7 months after their initial weight loss. The magnitude of weight loss was associated with cancer stage at cancer diagnosis ( p < 0.0001). Patients who experienced ā„ 7.5% UWL preācancer diagnosis had a median cancer stage of 3 whereas patients who experienced < 7.5% UWL had a median cancer stage of 2 at cancer diagnosis ( p < 0.0001). Relative to patients with ā„ 7.5% weight loss, the < 7.5% weight loss group had 73.7% more patients with Stage 1 disease ( p < 0.0001) and 32.5% fewer patients with Stage 4 disease ( p = 0.0006) resulting in median cancer stage increasing from Stages 2 to 3. Conclusions: UWL was missed in 43% of cancer cachexia patients despite 8.6% ± 0.3% body weight loss prior to cancer diagnosis. When recognized, documentation of UWL did not occur until 7 months after weight loss initiation. A greater magnitude of UWL was associated with more advanced disease at cancer diagnosis. Recognition and timely diagnosis of UWL will increase the percentage of patients with curable, earlyāstage disease.
- 1 January 2026
- Published byĀ WileyĀ inĀ Journal of Cachexia, Sarcopenia and Muscle
- Vol.Ā 17 Ā (2) , e70266
Open AccessUndetected Weight Loss Associates With Upstaging in Cancer Patients
Background: Unintentional weight loss (UWL) is the primary diagnostic parameter for cancer cachexia in the clinic. Prompt identification of UWL can lead to earlier diagnoses and interventions for cancer. This study investigates the frequency and timing of UWL documentation and diagnoses in a cohort of cancer patients with measured UWL and sought to understand how recognition of UWL is related to stage of disease at cancer diagnosis. Methods: A retrospective cohort of adult gastrointestinal and nonāsmall cell lung cancer patients with measured UWL was evaluated. Body weight histories were manually reviewed for UWL. Patients with intentional weight loss, weight loss related to fluid status or weight loss with unclear intention were excluded. Records were assessed for the use of UWLārelated International Classification of Diseases codes and documentation of UWL. ULW was considered missed if it was not documented or diagnosed by a healthcare provider. Associations between weight loss over time, documentation and/or diagnosis of UWL and stage of disease at cancer diagnosis were investigated through repeated measures mixed models and univariate and multivariate tests. Results: In total, 374 patients (24%) met the definition of UWL with an average weight loss of 8.6% ± 0.3%. UWL was missed in 161 (43%) patients with cancer cachexia. The odds of undetected UWL were greater in patients < 65 years old, with NSCLC, with obesity and who were White. In the 213 patients with recognized UWL, the documentation of UWL occurred approximately 7 months after their initial weight loss. The magnitude of weight loss was associated with cancer stage at cancer diagnosis ( p < 0.0001). Patients who experienced ā„ 7.5% UWL preācancer diagnosis had a median cancer stage of 3 whereas patients who experienced < 7.5% UWL had a median cancer stage of 2 at cancer diagnosis ( p < 0.0001). Relative to patients with ā„ 7.5% weight loss, the < 7.5% weight loss group had 73.7% more patients with Stage 1 disease ( p < 0.0001) and 32.5% fewer patients with Stage 4 disease ( p = 0.0006) resulting in median cancer stage increasing from Stages 2 to 3. Conclusions: UWL was missed in 43% of cancer cachexia patients despite 8.6% ± 0.3% body weight loss prior to cancer diagnosis. When recognized, documentation of UWL did not occur until 7 months after weight loss initiation. A greater magnitude of UWL was associated with more advanced disease at cancer diagnosis. Recognition and timely diagnosis of UWL will increase the percentage of patients with curable, earlyāstage disease.
- Open Access
Cancer Cachexia in STK11/LKB1 -mutated NSCLC is Dependent on Tumor-secreted GDF15
Cachexia is a wasting syndrome comprised of adipose, muscle, and weight loss observed in cancer patients. Tumor loss-of-function mutations in STK11/LKB1 , a regulator of the energy sensor AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are associated with cancer-related weight loss in NSCLC patients. Here we characterized the relevance of the NSCLC-associated cachexia factor growth differentiation factor 15 (GDF15) in several patient-derived and genetically engineered STK11/LKB1 -mutant NSCLC cachexia lines. Both tumor mRNA expression and serum concentrations of tumor-derived GDF15 were significantly elevated in multiple mice transplanted with patient-derived STK11/LKB1 -mutated NSCLC lines. GDF15 neutralizing antibody administered to mice transplanted with patient- or mouse-derived STK11/LKB1 -mutated NSCLC lines suppressed cachexia-associated adipose loss, muscle atrophy, and changes in body weight. The silencing of GDF15 in multiple human NSCLC lines was also sufficient to eliminate in vivo circulating GDF15 levels and abrogate cachexia induction, suggesting that tumor and not host tissues represent a key source of GDF15 production in these cancer models. Finally, reconstitution of wild-type STK11/LKB1 in a human STK11/LKB1 loss-of-function NSCLC line that normally induces cachexia in vivo correlated with the absence of tumor-secreted GDF15 and rescue from the cachexia phenotype. The current data provide evidence for tumor-secreted GDF15 as a conduit and a therapeutic target through which NSCLCs with STK11/LKB1 loss-of-function mutations promote cachexia-associated wasting.
Open AccessCancer Cachexia in STK11/LKB1 -mutated NSCLC is Dependent on Tumor-secreted GDF15
Cachexia is a wasting syndrome comprised of adipose, muscle, and weight loss observed in cancer patients. Tumor loss-of-function mutations in STK11/LKB1 , a regulator of the energy sensor AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are associated with cancer-related weight loss in NSCLC patients. Here we characterized the relevance of the NSCLC-associated cachexia factor growth differentiation factor 15 (GDF15) in several patient-derived and genetically engineered STK11/LKB1 -mutant NSCLC cachexia lines. Both tumor mRNA expression and serum concentrations of tumor-derived GDF15 were significantly elevated in multiple mice transplanted with patient-derived STK11/LKB1 -mutated NSCLC lines. GDF15 neutralizing antibody administered to mice transplanted with patient- or mouse-derived STK11/LKB1 -mutated NSCLC lines suppressed cachexia-associated adipose loss, muscle atrophy, and changes in body weight. The silencing of GDF15 in multiple human NSCLC lines was also sufficient to eliminate in vivo circulating GDF15 levels and abrogate cachexia induction, suggesting that tumor and not host tissues represent a key source of GDF15 production in these cancer models. Finally, reconstitution of wild-type STK11/LKB1 in a human STK11/LKB1 loss-of-function NSCLC line that normally induces cachexia in vivo correlated with the absence of tumor-secreted GDF15 and rescue from the cachexia phenotype. The current data provide evidence for tumor-secreted GDF15 as a conduit and a therapeutic target through which NSCLCs with STK11/LKB1 loss-of-function mutations promote cachexia-associated wasting.
- 24 November 2023
- Published byĀ Wolters Kluwer HealthĀ inĀ American Journal of Clinical Oncology
- Vol.Ā 47 Ā (2) , 49-55
Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in NonāSmall Cell Lung Cancer
Background: Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with nonāsmall cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated outcomes. Methods: Using an Institutional Tumor Registry, we evaluated all patients with stages of NSCLC treated at a tertiary care system from 2006 to 2013. We adopted the international consensus definition for cachexia, with staging designated by the registry and positron emission tomography. Radiotherapy delivery and intent were retrospectively assessed. Results: In total, 1330 patients with NSCLC were analyzed. Curative-intent radiotherapy was utilized equally between patients with cachexia and non-cachexia with stages I to III NSCLC. Conversely, significantly more patients with stage IV disease and cachexia received palliative radiotherapy versus those without (74% vs 63%, P = 0.006). Cachexia-associated survival was unchanged irrespective of tumor-directed radiation therapy with curative or palliative intent. In fact, pretreatment cachexia was associated with reduced survival for patients with stage III NSCLC receiving curative-intent radiotherapy (median survival = 23.9 vs 15.0 mo, P = 0.009). Finally, multivariate analysis identified pretreatment cachexia as an independent variable associated with worsened survival (hazard ratio = 1.31, CI: 1.14,1.52). Conclusion: Patients with advanced NSCLC with cachexia received more palliative-intent radiation than those without weight loss. Tumor-directed therapy in either a curative or palliative approach failed to alter cachexia patient survival across all stages of the disease. These findings offer critical information on the appropriate utilization of radiation in the management of patients with NSCLC with cachexia.
- 24 November 2023
- Published byĀ Wolters Kluwer HealthĀ inĀ American Journal of Clinical Oncology
- Vol.Ā 47 Ā (2) , 49-55
Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in NonāSmall Cell Lung Cancer
Background: Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with nonāsmall cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated outcomes. Methods: Using an Institutional Tumor Registry, we evaluated all patients with stages of NSCLC treated at a tertiary care system from 2006 to 2013. We adopted the international consensus definition for cachexia, with staging designated by the registry and positron emission tomography. Radiotherapy delivery and intent were retrospectively assessed. Results: In total, 1330 patients with NSCLC were analyzed. Curative-intent radiotherapy was utilized equally between patients with cachexia and non-cachexia with stages I to III NSCLC. Conversely, significantly more patients with stage IV disease and cachexia received palliative radiotherapy versus those without (74% vs 63%, P = 0.006). Cachexia-associated survival was unchanged irrespective of tumor-directed radiation therapy with curative or palliative intent. In fact, pretreatment cachexia was associated with reduced survival for patients with stage III NSCLC receiving curative-intent radiotherapy (median survival = 23.9 vs 15.0 mo, P = 0.009). Finally, multivariate analysis identified pretreatment cachexia as an independent variable associated with worsened survival (hazard ratio = 1.31, CI: 1.14,1.52). Conclusion: Patients with advanced NSCLC with cachexia received more palliative-intent radiation than those without weight loss. Tumor-directed therapy in either a curative or palliative approach failed to alter cachexia patient survival across all stages of the disease. These findings offer critical information on the appropriate utilization of radiation in the management of patients with NSCLC with cachexia.
- Open Access
- 24 April 2023
- Published byĀ American Society for Clinical InvestigationĀ inĀ JCI Insight
- Vol.Ā 8 Ā (8)
Tumor loss-of-function mutations in STK11/LKB1 induce cachexia
Cancer cachexia (CC), a wasting syndrome of muscle and adipose tissue resulting in weight loss, is observed in 50% of patients with solid tumors. Management of CC is limited by the absence of biomarkers and knowledge of molecules that drive its phenotype. To identify such molecules, we injected 54 human nonāsmall cell lung cancer (NSCLC) lines into immunodeficient mice, 17 of which produced an unambiguous phenotype of cachexia or non-cachexia. Whole-exome sequencing revealed that 8 of 10 cachexia lines, but none of the non-cachexia lines, possessed mutations in serine/threonine kinase 11 ( STK11/LKB1 ), a regulator of nutrient sensor AMPK. Silencing of STK11/LKB1 in human NSCLC and murine colorectal carcinoma lines conferred a cachexia phenotype after cell transplantation into immunodeficient (human NSCLC) and immunocompetent (murine colorectal carcinoma) models. This host wasting was associated with an alteration in the immune cell repertoire of the tumor microenvironments that led to increases in local mRNA expression and serum levels of CC-associated cytokines. Mutational analysis of circulating tumor DNA from patients with NSCLC identified 89% concordance between STK11/LKB1 mutations and weight loss at cancer diagnosis. The current data provide evidence that tumor STK11/LKB1 loss of function is a driver of CC, simultaneously serving as a genetic biomarker for this wasting syndrome.
- 24 April 2023
- Published byĀ American Society for Clinical InvestigationĀ inĀ JCI Insight
- Vol.Ā 8 Ā (8)
Open AccessTumor loss-of-function mutations in STK11/LKB1 induce cachexia
Cancer cachexia (CC), a wasting syndrome of muscle and adipose tissue resulting in weight loss, is observed in 50% of patients with solid tumors. Management of CC is limited by the absence of biomarkers and knowledge of molecules that drive its phenotype. To identify such molecules, we injected 54 human nonāsmall cell lung cancer (NSCLC) lines into immunodeficient mice, 17 of which produced an unambiguous phenotype of cachexia or non-cachexia. Whole-exome sequencing revealed that 8 of 10 cachexia lines, but none of the non-cachexia lines, possessed mutations in serine/threonine kinase 11 ( STK11/LKB1 ), a regulator of nutrient sensor AMPK. Silencing of STK11/LKB1 in human NSCLC and murine colorectal carcinoma lines conferred a cachexia phenotype after cell transplantation into immunodeficient (human NSCLC) and immunocompetent (murine colorectal carcinoma) models. This host wasting was associated with an alteration in the immune cell repertoire of the tumor microenvironments that led to increases in local mRNA expression and serum levels of CC-associated cytokines. Mutational analysis of circulating tumor DNA from patients with NSCLC identified 89% concordance between STK11/LKB1 mutations and weight loss at cancer diagnosis. The current data provide evidence that tumor STK11/LKB1 loss of function is a driver of CC, simultaneously serving as a genetic biomarker for this wasting syndrome.
- Open Access
- 11 March 2023
- Published byĀ ElsevierĀ inĀ JTO Clinical and Research Reports
- Vol.Ā 4 Ā (4) , 100496
Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report
- 11 March 2023
- Published byĀ ElsevierĀ inĀ JTO Clinical and Research Reports
- Vol.Ā 4 Ā (4) , 100496
Open AccessRacial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report
- Open Access
- 27 September 2022
- Published byĀ WileyĀ inĀ Journal of Cachexia, Sarcopenia and Muscle
- Vol.Ā 13 Ā (6) , 2920-2931
A preponderance of gastrointestinal cancer patients transition into cachexia syndrome
Background: Cancer cachexia is frequently documented by selfāreported, single timeāpoint weight histories. This approach lacks the granularity needed to fully elucidate the progression of cachexia syndrome. This study aimed to longitudinally assess body weight changes preā and postācancer diagnosis in gastrointestinal (GI) cancer patients.Methods: Body weights and relevant clinical data recorded in the electronic health record 12 months preā and postāGI cancer (colorectal, gastroesophageal, hepatobiliary and pancreatic) diagnosis were extracted. Weight loss was categorized by the International Consensus Definition for cachexia.Results: A total of 879 patients were included in the final cohort including patients diagnosed with colorectal (n = 317), hepatocellular (n = 185), biliary (n = 72), pancreatic (n = 186) or gastroesophageal (n = 119) cancer. Stage of disease was equally distributed. Patients without cachexia at diagnosis (n = 608) remained weight stable during the 12 months preādiagnosis (+0.5 ± 0.5% body weight; P = 0.99). Patients with cachexia at diagnosis (n = 271) remained weight stable 6 to 12 months prior to diagnosis (+0.4 ± 0.8%; P > 0.9999) and lost 8.7 ± 0.6% (P < 0.0001) within the 6 months preādiagnosis. Patients without cachexia at diagnosis lost more weight postādiagnosis (6.3 ± 0.6%) than patients with cachexia at diagnosis (4.7 ± 1.0%; P = 0.01). Preādiagnosis weight trajectories did not differ between primary malignancies or stage of disease in patients without or with cachexia at diagnosis (all P ā„ 0.05). Postādiagnosis weight trajectories did differ by primary malignancy (P ⤠0.0002) and stage (P < 0.0001). In both patients without and with cachexia at diagnosis, colorectal patients lost the least amount of weight postādiagnosis and gastroesophageal patients lost the most amount of weight postādiagnosis. Stage 4 patients without or with cachexia at diagnosis lost the most weight postādiagnosis (P ⤠0.0003). Regardless of cachexia status at diagnosis, patients lost more weight when treated with systemic therapy (7.1 ± 0.7%; P < 0.0001; n = 419) or radiation therapy (8.4 ± 1.4%; P = 0.02; n = 116) compared to those who did not. Patients who did not have surgery lost more weight postādiagnosis (7.6 ± 1.1%; P < 0.0001; n = 355) compared to those who did have surgery. By 12 months postādiagnosis, 83% of the surviving GI cancer patients in this cohort had transitioned into cachexia syndrome.Conclusions: Significant weight loss in patients with GI cancer cachexia at diagnosis initiates at least 6 months prior to diagnosis, and most patients will transition into cachexia syndrome postādiagnosis, regardless of preādiagnosis weight change and stage of disease. These findings punctuate the importance of weight surveillance in cancer detection and earlier palliative interventions postādiagnosis in the GI cancer patient population.
- 27 September 2022
- Published byĀ WileyĀ inĀ Journal of Cachexia, Sarcopenia and Muscle
- Vol.Ā 13 Ā (6) , 2920-2931
Open AccessA preponderance of gastrointestinal cancer patients transition into cachexia syndrome
Background: Cancer cachexia is frequently documented by selfāreported, single timeāpoint weight histories. This approach lacks the granularity needed to fully elucidate the progression of cachexia syndrome. This study aimed to longitudinally assess body weight changes preā and postācancer diagnosis in gastrointestinal (GI) cancer patients.Methods: Body weights and relevant clinical data recorded in the electronic health record 12 months preā and postāGI cancer (colorectal, gastroesophageal, hepatobiliary and pancreatic) diagnosis were extracted. Weight loss was categorized by the International Consensus Definition for cachexia.Results: A total of 879 patients were included in the final cohort including patients diagnosed with colorectal (n = 317), hepatocellular (n = 185), biliary (n = 72), pancreatic (n = 186) or gastroesophageal (n = 119) cancer. Stage of disease was equally distributed. Patients without cachexia at diagnosis (n = 608) remained weight stable during the 12 months preādiagnosis (+0.5 ± 0.5% body weight; P = 0.99). Patients with cachexia at diagnosis (n = 271) remained weight stable 6 to 12 months prior to diagnosis (+0.4 ± 0.8%; P > 0.9999) and lost 8.7 ± 0.6% (P < 0.0001) within the 6 months preādiagnosis. Patients without cachexia at diagnosis lost more weight postādiagnosis (6.3 ± 0.6%) than patients with cachexia at diagnosis (4.7 ± 1.0%; P = 0.01). Preādiagnosis weight trajectories did not differ between primary malignancies or stage of disease in patients without or with cachexia at diagnosis (all P ā„ 0.05). Postādiagnosis weight trajectories did differ by primary malignancy (P ⤠0.0002) and stage (P < 0.0001). In both patients without and with cachexia at diagnosis, colorectal patients lost the least amount of weight postādiagnosis and gastroesophageal patients lost the most amount of weight postādiagnosis. Stage 4 patients without or with cachexia at diagnosis lost the most weight postādiagnosis (P ⤠0.0003). Regardless of cachexia status at diagnosis, patients lost more weight when treated with systemic therapy (7.1 ± 0.7%; P < 0.0001; n = 419) or radiation therapy (8.4 ± 1.4%; P = 0.02; n = 116) compared to those who did not. Patients who did not have surgery lost more weight postādiagnosis (7.6 ± 1.1%; P < 0.0001; n = 355) compared to those who did have surgery. By 12 months postādiagnosis, 83% of the surviving GI cancer patients in this cohort had transitioned into cachexia syndrome.Conclusions: Significant weight loss in patients with GI cancer cachexia at diagnosis initiates at least 6 months prior to diagnosis, and most patients will transition into cachexia syndrome postādiagnosis, regardless of preādiagnosis weight change and stage of disease. These findings punctuate the importance of weight surveillance in cancer detection and earlier palliative interventions postādiagnosis in the GI cancer patient population.
- Open Access
- 24 June 2022
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Oncology
- Vol.Ā 12, 900712
Primary Tumor Fluorineā18 Fluorodeoxydglucose (18FāFDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival
Aim: To investigate the diagnostic potential of and associations between tumor 18FāFDG uptake on PET imaging and cancer-associated weight loss.Methods: 774 non-small cell lung cancer (NSCLC) patients with pre-treatment PET evaluated between 2006 and 2014 were identified. Using the international validated definition of cachexia, the presence of clinically significant pretreatment cancer-associated weight loss (WL) was retrospectively determined. Maximum Standardized Uptake Value (SUVMax) of 18FāFDG was recorded and dichotomized based on 3 experimental cutpoints for survival analyses. Each SUVMax cutpoint prioritized either survival differences, total cohort comparison sample sizes, or sample size by stage. Patient outcomes and associations between SUVMax and cancer-associated weight loss were assessed by multivariate, categorical, and survival analyses.Results: Patients were found to have an increased likelihood of having WL at diagnosis associated with increasing primary tumor SUVMax after controlling for potentially confounding patient and tumor characteristics on multivariate logistic regression (OR 1.038; 95% CI: 1.012, 1.064; P=0.0037). After stratifying the cohort by WL and dichotomized SUVMax, both factors were found to be relevant in predicting survival outcomes when the alternative variable was constant. Of note, the most striking survival differences contributed by WL status occurred in high SUVMax groups, where the presence of WL predicted a median survival time detriment of up to 10 months, significant regardless of cutpoint determination method applied to categorize high SUVMax patients. SUVMax classification was found to be most consistently relevant in both WL and no WL groups.Conclusions: The significant positive association between significant pretreatment cancer-associated weight loss and primary tumor SUVMax underscores increased glucose uptake as a component of catabolic tumor phenotypes. This substantiates 18FāFDG PET analysis as a prospective tool for assessment of cancer-associated weight loss and corresponding survival outcomes. Furthermore, the survival differences observed between WL groups across multiple SUVMax classifications supports the importance of weight loss monitoring in oncologic workups. Weight loss in the setting of NSCLCs with higher metabolic activity as determined by 18FāFDG PET signal should encourage more aggressive and earlier palliative care interventions.
- 24 June 2022
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Oncology
- Vol.Ā 12, 900712
Open AccessPrimary Tumor Fluorineā18 Fluorodeoxydglucose (18FāFDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival
Aim: To investigate the diagnostic potential of and associations between tumor 18FāFDG uptake on PET imaging and cancer-associated weight loss.Methods: 774 non-small cell lung cancer (NSCLC) patients with pre-treatment PET evaluated between 2006 and 2014 were identified. Using the international validated definition of cachexia, the presence of clinically significant pretreatment cancer-associated weight loss (WL) was retrospectively determined. Maximum Standardized Uptake Value (SUVMax) of 18FāFDG was recorded and dichotomized based on 3 experimental cutpoints for survival analyses. Each SUVMax cutpoint prioritized either survival differences, total cohort comparison sample sizes, or sample size by stage. Patient outcomes and associations between SUVMax and cancer-associated weight loss were assessed by multivariate, categorical, and survival analyses.Results: Patients were found to have an increased likelihood of having WL at diagnosis associated with increasing primary tumor SUVMax after controlling for potentially confounding patient and tumor characteristics on multivariate logistic regression (OR 1.038; 95% CI: 1.012, 1.064; P=0.0037). After stratifying the cohort by WL and dichotomized SUVMax, both factors were found to be relevant in predicting survival outcomes when the alternative variable was constant. Of note, the most striking survival differences contributed by WL status occurred in high SUVMax groups, where the presence of WL predicted a median survival time detriment of up to 10 months, significant regardless of cutpoint determination method applied to categorize high SUVMax patients. SUVMax classification was found to be most consistently relevant in both WL and no WL groups.Conclusions: The significant positive association between significant pretreatment cancer-associated weight loss and primary tumor SUVMax underscores increased glucose uptake as a component of catabolic tumor phenotypes. This substantiates 18FāFDG PET analysis as a prospective tool for assessment of cancer-associated weight loss and corresponding survival outcomes. Furthermore, the survival differences observed between WL groups across multiple SUVMax classifications supports the importance of weight loss monitoring in oncologic workups. Weight loss in the setting of NSCLCs with higher metabolic activity as determined by 18FāFDG PET signal should encourage more aggressive and earlier palliative care interventions.